Many are effectively falling through the cracks
In New Zealand, a population long rendered invisible by gaps in health data has finally been counted — and what the numbers reveal is a quiet crisis. A University of Otago study, the first of its kind to use linked national datasets, finds that people living with ME/CFS face not only profound physical burden but sustained exclusion from work, inadequate access to disability support, and economic hardship that compounds over years. It is a story about what happens when a condition is poorly understood by the systems meant to respond to it — and about the human cost of that misunderstanding.
- Despite using emergency departments far more than the general population and often taking ten or more medications a year, people with ME/CFS access disability support services at less than a quarter the rate of other benefit recipients.
- With only 18% employed compared to over 80% of the general population, ME/CFS patients are not experiencing a temporary setback — nearly half have been on continuous benefit for five years, signalling deep, structural workforce exclusion.
- Māori and other ethnic groups are strikingly underrepresented in the diagnosed population, pointing not to lower disease rates but to systemic barriers in diagnosis and access that leave entire communities uncounted and unserved.
- Researchers, patient advocates, and clinicians are now calling for urgent reform — better diagnostic pathways, integrated care models, and data systems capable of capturing who is truly affected and what they actually need.
A University of Otago study, published in BMC Public Health, has for the first time used linked national datasets to examine how people with ME/CFS are faring across health, employment, and access to support in New Zealand. The findings are sobering. Among nearly 1,900 working-age people receiving a health or disability benefit with a recorded ME/CFS diagnosis, the health burden was high — frequent emergency department visits, and nearly one in three dispensed ten or more different medications in a single year. Yet despite these significant needs, only 1.6 percent accessed disability support services, compared to 7.2 percent among other benefit recipients. High need, low access.
The economic picture is equally stark. Just 18 percent of people with ME/CFS were employed, against more than 80 percent of the general population. Nearly two-thirds relied on the Supported Living Payment, and almost half had received a benefit continuously over five years — a pattern that speaks not to temporary hardship but to long-term exclusion from working life. Lead author Dr Nick Bowden described ME/CFS as a largely invisible population experiencing significant unmet need, noting that the condition remains poorly understood across the health system.
The study also revealed troubling inequities in who gets diagnosed. The identified population was overwhelmingly European, with Māori and other ethnic groups substantially underrepresented — a gap researchers attributed to barriers in diagnosis and access rather than true differences in prevalence. Fiona Charlton of the Associated New Zealand ME Society, a co-author, argued that current support systems are simply not designed for chronic, fluctuating conditions, leaving many people too unwell to work but unable to access meaningful help.
The researchers are calling for urgent reform: clearer diagnostic pathways, more integrated and person-centred care, and improved data collection to capture the full diversity of those affected. The evidence of the challenge is now on the table. Whether health and social systems will rise to meet it remains an open question.
A new study from the University of Otago has pulled back the curtain on a population that has largely remained invisible in New Zealand's health data: people living with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. The research, published in BMC Public Health, is the first in the country to use linked national datasets to map out how people with ME/CFS are actually faring—across their health, their work lives, and their access to support. What it found is sobering.
The study identified nearly 1,900 working-age people receiving a health or disability benefit with a recorded ME/CFS diagnosis, then compared their outcomes to both other benefit recipients and the general population. The health picture alone tells part of the story. People with ME/CFS used emergency departments far more frequently than the general population and consumed medications at a striking rate: nearly one in three were dispensed ten or more different medications in a single year, more than double the rate seen in the broader population. Yet despite these substantial health needs, access to intensive disability support was remarkably thin. Only 1.6 percent of the ME/CFS group accessed disability support services—a figure that stands in sharp contrast to the 7.2 percent rate among other benefit recipients. The mismatch is stark: high need, low access.
The economic consequences have been severe and durable. Just 18 percent of people with ME/CFS were employed, compared to more than 80 percent of the general population. Nearly two-thirds relied on the Supported Living Payment, and almost half had received a benefit continuously over the previous five years. This is not a temporary dip in employment. This is sustained exclusion from the workforce, with all the financial precarity and social isolation that follows. Dr Nick Bowden, the study's lead author from Otago's Department of Paediatrics and Child Health, described the findings as concerning and called ME/CFS a largely invisible population experiencing significant unmet need. The condition itself remains poorly understood and under-recognised across the health system, he noted.
The research also exposed inequities in who gets diagnosed and who receives care. The identified ME/CFS population was overwhelmingly European, with Māori and other ethnic groups substantially underrepresented. This likely reflects not true differences in disease prevalence, but rather barriers to diagnosis and access to services—a gap that Emeritus Professor Warren Tate, a co-author, flagged as urgent. There is, he said, a critical need for wider understanding of ME/CFS across all parts of the health sector, and for education about research-based best practice in managing the condition across all ethnic groups.
Fiona Charlton, president of the Associated New Zealand ME Society and a co-author on the study, framed the findings as evidence of a fundamental design problem. Current support systems, she explained, are not well suited to chronic, fluctuating conditions like ME/CFS. Many people are effectively falling through the cracks—too unwell to work, but not accessing the support that might help them navigate their condition. Bowden and his colleagues are calling for urgent improvements: better diagnostic pathways, more integrated and person-centred models of care, and improved data collection that captures the full picture of who is affected. The research, he said, is ultimately about making people with ME/CFS visible in the data and in policy. The evidence of their challenges is now clear. What remains to be seen is whether the health and social systems will respond.
Notable Quotes
ME/CFS is a complex and often debilitating condition, but it remains poorly understood and under-recognised. This study provides the first national picture of how people with ME/CFS are faring across multiple aspects of life, and the results are concerning.— Dr Nick Bowden, lead author
Current support systems are not well designed for people with chronic, fluctuating conditions like ME/CFS. Many are effectively falling through the cracks.— Fiona Charlton, Associated New Zealand ME Society President
The Hearth Conversation Another angle on the story
Why does it matter that this is the first national study using linked data? Couldn't we have known this from smaller surveys?
Linked data is different because it follows real people through actual systems—their health records, their benefit payments, their emergency department visits. A survey asks people to remember and report. This data shows what actually happened. It's harder to dismiss.
The medication number jumped out at me. Why would ME/CFS patients need so many drugs?
ME/CFS is a complex condition. People often have pain, sleep problems, cognitive issues, infections that keep recurring. They're also managing the cascade of problems that come from being severely fatigued—depression, anxiety, secondary conditions. The medications reflect that complexity, but they also suggest people are struggling to manage symptoms without getting to the root of the problem.
The disability support gap is striking. Only 1.6 percent accessing services. Why so low?
The system wasn't built for this. Disability support eligibility often assumes a stable, predictable disability. ME/CFS fluctuates wildly. Someone might have a good week and look functional, then crash for months. The bureaucracy can't track that. And many people don't know they're eligible, or they've been told they're not sick enough.
What does it mean that the identified population is overwhelmingly European?
It almost certainly means Māori and Pacific people with ME/CFS aren't being diagnosed or aren't showing up in the benefit system. That could be because of barriers to accessing diagnosis, cultural factors in how illness is reported, or because they're managing without going on a benefit. Either way, the health system is missing them.
What happens next? Does this study change anything?
That's the real question. The researchers are calling for better diagnostic pathways, integrated care models, improved data collection. But calling for change and getting it are different things. The study makes the problem visible. Whether anyone acts on it depends on whether policymakers decide this population matters enough to redesign systems around them.